Doxorubicin chemotherapy in young (3-month) and aged (20-month) male and female mice triggered accelerated skeletal aging — trabecular bone loss, increased marrow adiposity, and suppression of osteogenic transcription factors Alpl, Runx2, and Dmp1 — alongside a cortical bone proteomic signature of glycolytic shift and inflammatory collagen remodeling. Senolytic co-treatment with dasatinib/quercetin (DQ) partially reversed these molecular changes, with strongest effects in aged females, though macrostructural trabecular recovery remained modest.
Chemotherapy-induced bone loss is a clinically underappreciated toxicity affecting cancer survivors across age groups, and this study adds mechanistic resolution to a growing literature implicating the senescence-associated secretory phenotype (SASP) as a key driver. The DQ combination — already in human trials for idiopathic pulmonary fibrosis and diabetic kidney disease — showing efficacy in this skeletal context is notable because it bridges a plausible mechanism to a clinically available intervention. The sex-dependent effect, more severe in females, aligns with known estrogen-senescence interactions and has immediate implications for breast cancer survivors, a large and growing population.
Critical limitations temper enthusiasm: this is a rodent model, DQ was co-administered rather than given as a rescue therapy post-chemotherapy, and trabecular architecture did not meaningfully recover despite favorable molecular signals — suggesting molecular remodeling precedes structural repair by an unknown lag. Whether extended DQ treatment or sequential dosing would restore bone density in humans requires dedicated trials. Categorically, this is a solid mechanistic advance — incremental rather than paradigm-shifting — but it credibly positions senolytics as adjuncts to oncologic bone-protection protocols.
